Back to discover
Drug

Potassium

In clinical development
Emerging researchLate-stage developmentSteady momentum
Also known as K, Kalium, Neutra-Phos-K, Potasio+5 more

K, Kalium, Neutra-Phos-K, Potasio, K - Potassium, Potassium metal, Potassium, elemental, Potassium, metal, potassium(1+).

6
Research papers
1
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

Clinical trial2026-04-06Results expected Q2 2027 · ClinicalTrials.gov

ASPEN Consensus Recommendations for Refeeding Syndrome.

Research2020-03-02Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition

The Physiology of the Gastric Parietal Cell.

Research2019-10-31Physiological reviews

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Potassium
Aliases & brands
KKaliumNeutra-Phos-KPotasioK - PotassiumPotassium metalPotassium, elementalPotassium, metalpotassium(1+)
RxNorm CUI
8588
ChEMBL ID
CHEMBL1201290
UNII
RWP5GA015D

Clinical trials

7 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
7
registered trials across all phases
LATEST COMPLETION 2024
1
Active studies
1
Recruiting
4
Late-stage (III+)
5
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 7
Phase 12Phase 21Phase 32Phase 41Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

6 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20172024
Most influential
Recent papers
Major research themes8
Aging1Astrocytes1Diabetes Mellitus, Type 21Dietary Supplements1Fragile X Messenger Ribonucleoprotein 11Fragile X Syndrome1Kidney Calculi1Neurodegenerative Diseases1
Journals, researchers & institutions
Top journals
  • Brain : a journal of neurology1
  • Frontiers in endocrinology1
  • Kidney international1
  • Nature communications1
  • Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition1
  • Physiological reviews1
Leading researchers
  • Adams SC1
  • Ayers P1
  • Bataveljic D1
  • Bemelmans AP1
  • Berdahl GJ1
  • Blanchard A1
  • Bockenhauer D1
  • Bolignano D1
Leading institutions
free-text, unnormalised
  • Akron Children's Hospital1
  • Boston Children's Hospital1
  • Center for Basic and Translational Neuroscience1
  • Center for Interdisciplinary Research in Biology1
  • Center for Molecular Medicine1
  • Center for Translational Neuromedicine1

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials